Tumor-induced osteomalacia: pre- and postoperative biochemical findings
- PMID: 1963876
- DOI: 10.1055/s-2007-1004992
Tumor-induced osteomalacia: pre- and postoperative biochemical findings
Abstract
A patient with late-onset hypophosphatemic osteomalacia was treated with oral supplements of phosphate (1.5 g/day) and calcitriol (1.5-3.0 micrograms/day) for 17 months, before a slowly growing tumor in the first metatarsal space became evident. Before treatment concentrations of inorganic phosphate (Pi) and calcitriol in serum and tubular reabsorption of phosphate (TRP) were very low, calcium and parathyroid hormone (PTH) in serum were normal, urinary cyclic adenosine monophosphate (cAMP) was strongly elevated. During the first weeks of conservative treatment urinary cAMP returned to normal; concomitantly there was a transient slight fall in PTH. Serum calcium was in the low normal range and did not significantly change during conservative therapy. During the further course PTH rose to pretreatment values, but urinary cAMP remained normal. When the dose of calcitriol was elevated to 3 x 1.0 micrograms/day, leading to slightly elevated serum concentrations of this substance, Pi in serum rose to the low normal range, but TRP remained low and bone pain, although improved, did not subside. The tumor was locally excised. Postoperatively calcitriol concentration became elevated within 48 hours and remained so for several weeks. The rise in calcitriol concentration preceded the elevation of Pi in serum, not, however, the increase of TRP. The elevation of urinary cyclic AMP before therapy may have been due to a direct action of the substance secreted by the tumor.
Similar articles
-
Metabolic studies in a patient with idiopathic hypophosphatemic osteomalacia.Isr J Med Sci. 1988 Jan;24(1):46-50. Isr J Med Sci. 1988. PMID: 3346150
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Bone densitometry in a patient with hypophosphatemic osteomalacia.J Bone Miner Metab. 2004;22(5):514-7. doi: 10.1007/s00774-004-0516-0. J Bone Miner Metab. 2004. PMID: 15316875
-
Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.Pediatrics. 1983 Apr;71(4):559-67. Pediatrics. 1983. PMID: 6300745
-
Review and update: oncogenic osteomalacia-rickets.Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):317-33. doi: 10.3109/01913129109016242. Ultrastruct Pathol. 1991. PMID: 1755097 Review.
Cited by
-
Phosphaturic mesenchymal tumors: what an endocrinologist should know.J Endocrinol Invest. 2018 Oct;41(10):1173-1184. doi: 10.1007/s40618-018-0849-5. Epub 2018 Feb 14. J Endocrinol Invest. 2018. PMID: 29446010 Review.
-
Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report.Korean J Intern Med. 1997 Jan;12(1):89-95. doi: 10.3904/kjim.1997.12.1.89. Korean J Intern Med. 1997. PMID: 9159046 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous